http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2011127422-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate | 2009-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2011127422-A |
| titleOfInvention | ALBUMINE-BINDING PEPTIDE-MEDIATED AFFECTED IMPACT IMPACT ON DISEASES |
| abstract | 1. A composition comprising a conjugate molecule containing a peptide ligand domain conjugated to an active substance, where the peptide ligand domain contains a peptide with the sequence SEQ ID NO: 1-67 or their homologs. 2. The composition of claim 1, wherein the peptide ligand domain has an affinity for human serum albumin, characterized by an equilibrium dissociation constant (Kd) of about 700 μM or less. The composition according to claim 1, the result of the introduction of which to the animal is: (a) an increase in the delivery of the active substance to the affected area relative to the delivery of one active substance, or (b) a half-life in blood of the active substance that is longer than the half-life in blood obtained with the introduction of one active substance. 4. The composition of claim 2, wherein the conjugate molecule contains two or more peptides, each peptide containing one or more albumin binding domains of peptide ligands. The composition according to claim 4, in which each peptide ligand domain contains a peptide with the sequence of SEQ ID NO: 1-67 or their homologues. The composition of claim 1, wherein the disease-affected area is a zone affected by a neoplastic, proliferative, or inflammatory disease. The composition of claim 1, wherein said active substance comprises a therapeutic substance or a diagnostic substance. The composition of claim 7, wherein said active substance is a therapeutic substance selected from the group consisting of tyrosine kinase inhibitors, kinase inhibitors, biologically active substances, biological molecules, radionuclides, adriamycin, ansamycin |
| priorityDate | 2008-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 175.